Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Beril Erdogdu"'
Autor:
Ales Varabyou, Markus J. Sommer, Beril Erdogdu, Ida Shinder, Ilia Minkin, Kuan-Hao Chao, Sukhwan Park, Jakob Heinz, Christopher Pockrandt, Alaina Shumate, Natalia Rincon, Daniela Puiu, Martin Steinegger, Steven L. Salzberg, Mihaela Pertea
Publikováno v:
Genome Biology, Vol 24, Iss 1, Pp 1-16 (2023)
Abstract CHESS 3 represents an improved human gene catalog based on nearly 10,000 RNA-seq experiments across 54 body sites. It significantly improves current genome annotation by integrating the latest reference data and algorithms, machine learning
Externí odkaz:
https://doaj.org/article/20e94c3931d244779a6859df07d6e08f
Autor:
Ales Varabyou, Markus J. Sommer, Beril Erdogdu, Ida Shinder, Ilia Minkin, Kuan-Hao Chao, Sukhwan Park, Jakob Heinz, Christopher Pockrandt, Alaina Shumate, Natalia Rincon, Daniela Puiu, Martin Steinegger, Steven L. Salzberg, Mihaela Pertea
The original CHESS database of human genes was assembled from nearly 10,000 RNA sequencing experiments in 53 human body sites produced by the Genotype-Tissue Expression (GTEx) project, and then augmented with genes from other databases to yield a com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26cb2390259bcb782b79850651274db3
https://doi.org/10.1101/2022.12.21.521274
https://doi.org/10.1101/2022.12.21.521274
Autor:
Deanna M. Tiek, Beril Erdogdu, Roham Razaghi, Lu Jin, Norah Sadowski, Carla Alamillo-Ferrer, J. Robert Hogg, Bassem R. Haddad, David H. Drewry, Carrow I. Wells, Julie E. Pickett, Xiao Song, Anshika Goenka, Bo Hu, Samuel A. Goldlust, William J. Zuercher, Mihaela Pertea, Winston Timp, Shi-Yuan Cheng, Rebecca B. Riggins
Publikováno v:
Science Advances. 8
Temozolomide (TMZ) is a chemotherapeutic agent that has been the first-line standard of care for the aggressive brain cancer glioblastoma (GBM) since 2005. Although initially beneficial, TMZ resistance is universal and second-line interventions are a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4533b37d0598e3c08e998a011ccb979
https://doi.org/10.1126/sciadv.abn3471
https://doi.org/10.1126/sciadv.abn3471
Autor:
Lu Jin, Julie E. Pickett, Anshika Goenka, William J. Zuercher, Norah Sadowski, Bassem R. Haddad, Carla Alamillo-Ferrer, Roham Razaghi, Shi Yuan Cheng, Beril Erdogdu, Samuel L Goldlust, Mihaela Pertea, Bo Hu, Xiao Song, David H. Drewry, Carrow I. Wells, Deanna Tiek, Winston Timp, J. Robert Hogg, Rebecca B. Riggins
Temozolomide (TMZ) is a chemotherapeutic agent that has been the first-line standard of care for the aggressive brain cancer glioblastoma (GBM) since 2005. Though initially beneficial, TMZ- resistance is universal and second-line interventions are an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8c83da0ce8a0ec053517a9f0095e4a2
Autor:
Axel Moyal, Christopher J. Magnani, Dylan J. Peterson, Selen Bozkurt, Beril Erdogdu, James D. Brooks, Tina Hernandez-Boussard
Publikováno v:
Journal of Urology. 206
INTRODUCTION AND OBJECTIVE:The utility of prostate-specific antigen kinetics (PSAk) in Active Surveillance (AS) of low-risk prostate cancer remains controversial. The Prostate Active Surveillance S...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bedb6116a74b1cdfdfa02ecc5909268b
https://doi.org/10.1097/ju.0000000000002102.07
https://doi.org/10.1097/ju.0000000000002102.07
Autor:
Christopher J. Magnani, Beril Erdogdu, Laurence C. Baker, Nicolas Bievre, James D. Brooks, Tina Hernandez-Boussard
Publikováno v:
Journal of Urology. 203
INTRODUCTION AND OBJECTIVE:Active Surveillance (AS) has gained traction as a first line approach for men diagnosed with low-risk early-stage prostate cancer; however, identifying occult high grade ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa4e8cf014550b171a8fb585d7e8a07f
https://doi.org/10.1097/ju.0000000000000856.012
https://doi.org/10.1097/ju.0000000000000856.012